The United States Government Printing Office (GPO) was created in June 1860, and is an agency of the the U.S. federal government based in Washington D.C. The office prints documents produced by and for the federal government, including Congress, the Supreme Court, the Executive Office of the President and other executive departments, and independent agencies. Congressional Committee Prints are publications issued by Congressional Committees that include topics related to their legislative or research activities. The prints are a fine resource for statistical and historical information, and for legislative analysis. The topics of these Prints vary greatly due to the different concerns and actions of each committee. Some basic categories of Congressional Committee Prints are: situational studies, draft reports and bills, hearings, directories, statistical materials, investigative reports, historical reports, confidential staff reports, and legislative analyses.

*Winner of an honorable mention from theSociety for Social Work and ResearchforOutstanding Social Work Book Award Mad Science argues that the fundamental claims of modern American psychiatry are based on misconceived, flawed, and distorted science. The authors address multiple paradoxes in American mental health research, including the remaking of coercion into scientific psychiatric treatment, the adoption of an unscientific diagnostic system that controls the distribution of services, and how drug treatments have failed to improve the mental health outcome. When it comes to understanding and treating mental illness, distortions of research are not rare, misinterpretation of data is not isolated, and bogus claims of success are not voiced by isolated researchers seeking aggrandizement. This book’s detailed analysis of coercion and community treatment, diagnosis, and psychopharmacology reveals that these characteristics are endemic, institutional, and protected in psychiatry. They are not just bad science, but mad science. This book provides an engaging and readable scientific and social critique of current mental health practices. The authors are scholars, researchers, and clinicians who have written extensively about community care, diagnosis, and psychoactive drugs. This paperback edition makes Mad Science accessible to all specialists in the field as well as to the informed public.

Charles Ferguson, who electrified the world with his Academy Award-winning documentary, Inside Job, now reveals how rogues with influence have taken over the country and are driving it to financial and social ruin. In Predator Nation, Ferguson exposes the networks of academic, government, and congressional influence--in all recent administrations, including Obama's--that prepared the path to conquest. He reveals how once-revered figures like Alan Greenspan and Larry Summers have become mere courtiers to the elite. And based on many newly released court filings, he details the extent of the crimes--there is no other word--committed in the frenzied chase for storied wealth that marked the 2000s. And, finally, he lays out a brief plan of action for how we might take it back.

This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.

To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.

Significant progress has been made in advanced packaging in recent years. Several new packaging techniques have been developed and new packaging materials have been introduced. This book provides a comprehensive overview of the recent developments in this industry, particularly in the areas of microelectronics, optoelectronics, digital health, and bio-medical applications. The book discusses established techniques, as well as emerging technologies, in order to provide readers with the most up-to-date developments in advanced packaging.

On July 30-31, 2018, the National Academies of Sciences, Engineering, and Medicine held a workshop titled Continuous Manufacturing for the Modernization of Pharmaceutical Production. This workshop discussed the business and regulatory concerns associated with adopting continuous manufacturing techniques to produce biologics such as enzymes, monoclonal antibodies, and vaccines. The participants also discussed specific challenges for integration across the manufacturing system, including upstream and downstream processes, analytical techniques, and drug product development. The workshop addressed these challenges broadly across the biologics domain but focused particularly on drug categories of greatest FDA and industrial interest such as monoclonal antibodies and vaccines. This publication summarizes the presentations and discussions from the workshop.